🇺🇸 Sitravatinib in United States

Sitravatinib (sitravatinib) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Sitravatinib in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Sitravatinib approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Sitravatinib in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Sitravatinib cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.